The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech ...

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

Denali Therapeutics (NASDAQ:DNLI) on Monday said cash, cash equivalents, and marketable securities were approximately $1.28 billion as of September 30, 2024. Denali anticipates its cash runway will ...

DNLI opened at $21.25 on Tuesday. The stock has a fifty day moving average of $24.23 and a 200-day moving average of $24.86. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two ...

NASDAQ:DNLI opened at $21.25 on Friday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The company has a fifty day moving average price of $24.23 and a 200 ...